Q1 Earnings Forecast for SYRS Issued By HC Wainwright

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for shares of Syros Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.70) for the quarter. HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Syros Pharmaceuticals’ current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.68) EPS and Q4 2025 earnings at ($0.69) EPS.

A number of other equities analysts have also weighed in on SYRS. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. Piper Sandler reiterated an “overweight” rating and set a $5.00 price target (down from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. StockNews.com cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. Finally, TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Trading Down 5.7 %

Shares of SYRS stock opened at $0.26 on Friday. Syros Pharmaceuticals has a twelve month low of $0.25 and a twelve month high of $8.17. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97. The business’s 50 day moving average is $2.02 and its two-hundred day moving average is $3.79. The company has a market capitalization of $6.96 million, a P/E ratio of -0.09 and a beta of 1.59.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same period last year, the firm posted ($1.35) earnings per share.

Hedge Funds Weigh In On Syros Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Syros Pharmaceuticals by 21.3% during the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after buying an additional 163,234 shares in the last quarter. Opaleye Management Inc. grew its stake in Syros Pharmaceuticals by 119.1% in the 1st quarter. Opaleye Management Inc. now owns 787,545 shares of the company’s stock worth $4,213,000 after acquiring an additional 428,175 shares during the period. Kennedy Capital Management LLC acquired a new position in Syros Pharmaceuticals in the 1st quarter valued at $2,166,000. Acadian Asset Management LLC lifted its stake in shares of Syros Pharmaceuticals by 101.5% during the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after purchasing an additional 17,416 shares during the period. Finally, Certuity LLC acquired a new stake in shares of Syros Pharmaceuticals during the second quarter worth $109,000. 91.47% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Jason Haas acquired 45,344 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average cost of $1.68 per share, for a total transaction of $76,177.92. Following the transaction, the chief financial officer now directly owns 124,552 shares of the company’s stock, valued at approximately $209,247.36. This trade represents a 57.25 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Conley Chee bought 50,000 shares of Syros Pharmaceuticals stock in a transaction that occurred on Tuesday, September 10th. The stock was bought at an average cost of $1.51 per share, for a total transaction of $75,500.00. Following the purchase, the chief executive officer now owns 72,504 shares in the company, valued at $109,481.04. This represents a 222.18 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 130,707 shares of company stock worth $206,491. 12.26% of the stock is owned by company insiders.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.